MORPHIC HOLDING INC (MORF)
US61775R1059 - Common Stock
We assign a fundamental rating of 3 out of 10 to MORF. MORF was compared to 565 industry peers in the Biotechnology industry. While MORF has a great health rating, there are worries on its profitability. MORF does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
MORF had negative earnings in the past year.
In the past year MORF has reported a negative cash flow from operations.
In the past 5 years MORF always reported negative net income.
MORF had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of MORF (-27.83%) is better than 71.70% of its industry peers.
MORF has a better Return On Equity (-29.08%) than 81.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.83% | ||
| ROE | -29.08% | ||
| ROIC | N/A |
ROA(3y)-19.83%
ROA(5y)-19.11%
ROE(3y)-22.37%
ROE(5y)-25.77%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MORF does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MORF does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MORF has more shares outstanding
MORF has more shares outstanding than it did 5 years ago.
There is no outstanding debt for MORF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
MORF has an Altman-Z score of 60.78. This indicates that MORF is financially healthy and has little risk of bankruptcy at the moment.
MORF has a Altman-Z score of 60.78. This is amongst the best in the industry. MORF outperforms 98.42% of its industry peers.
There is no outstanding debt for MORF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 60.78 |
ROIC/WACCN/A
WACC10.56%
2.3 Liquidity
A Current Ratio of 24.13 indicates that MORF has no problem at all paying its short term obligations.
MORF's Current ratio of 24.13 is amongst the best of the industry. MORF outperforms 95.43% of its industry peers.
A Quick Ratio of 24.13 indicates that MORF has no problem at all paying its short term obligations.
MORF has a better Quick ratio (24.13) than 95.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 24.13 | ||
| Quick Ratio | 24.13 |
3. Growth
3.1 Past
The earnings per share for MORF have decreased strongly by -15.74% in the last year.
Looking at the last year, MORF shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
Measured over the past years, MORF shows a very negative growth in Revenue. The Revenue has been decreasing by -31.12% on average per year.
EPS 1Y (TTM)-15.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-77.37%
Revenue growth 5Y-31.12%
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, MORF will show a small growth in Earnings Per Share. The EPS will grow by 0.11% on average per year.
Based on estimates for the next years, MORF will show a very strong growth in Revenue. The Revenue will grow by 213.82% on average per year.
EPS Next Y-16.05%
EPS Next 2Y-11.1%
EPS Next 3Y-8.78%
EPS Next 5Y0.11%
Revenue Next Year-50.42%
Revenue Next 2Y-24.72%
Revenue Next 3Y-7.43%
Revenue Next 5Y213.82%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MORF. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MORF. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MORF's earnings are expected to decrease with -8.78% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.1%
EPS Next 3Y-8.78%
5. Dividend
5.1 Amount
MORF does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MORPHIC HOLDING INC
NASDAQ:MORF (8/15/2024, 8:13:37 PM)
After market: 56.99 0 (0%)56.99
+0.02 (+0.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.85B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.83% | ||
| ROE | -29.08% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 24.13 | ||
| Quick Ratio | 24.13 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-15.74%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-16.05%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-100%
Revenue growth 3Y-77.37%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y